Selank Dosage Guide: Intranasal Anxiolytic Peptide, Half-Life & Research Protocol

A comprehensive research guide to Selank — mechanism of action, intranasal dosing protocols (250–750 mcg), reconstitution, half-life, comparison with benzodiazepines, and storage requirements.

TL;DR

• Selank is a heptapeptide anxiolytic derived from tuftsin, administered intranasally at 250–750 mcg per dose
• Its mechanism involves enkephalinase inhibition, GABAergic potentiation, and serotonin system modulation
• Unlike benzodiazepines, Selank does not appear to cause sedation, tolerance, or physical dependence in research models
• Memory enhancement and cognitive clarity have been observed alongside anxiolytic effects in preclinical and early clinical studies

Disclaimer: For educational and research purposes only — not medical advice.

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Structurally, it is an analogue of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Gly-Glu-Pro sequence to improve metabolic stability. It has been investigated primarily as an anxiolytic and nootropic agent, with a pharmacological profile that differs substantially from classical anxiolytics such as benzodiazepines or SSRIs. This guide reviews the current research on Selank's mechanism, dosing, administration, and storage for research purposes.

Mechanism of Action: Enkephalinase Inhibition and GABAergic Modulation

Selank's anxiolytic properties appear to arise from at least two distinct molecular pathways. First, the peptide acts as an inhibitor of enkephalinase (neprilysin), the primary enzyme responsible for degrading endogenous enkephalins. By slowing enkephalin breakdown, Selank effectively prolongs the activity of these endogenous opioid peptides at mu and delta receptors, producing anxiolysis without the sedation or euphoria associated with exogenous opioids.

Second, research has documented that Selank modulates GABAergic neurotransmission. Unlike benzodiazepines, which directly bind to GABA-A receptor allosteric sites, Selank appears to influence GABA signaling indirectly — potentially by modulating GABA transaminase activity or by altering receptor expression patterns. This distinction may explain why Selank does not produce the muscle relaxation, cognitive blunting, or physical dependence characteristic of benzodiazepine use.

Additionally, Selank has been shown to influence serotonergic neurotransmission, with observed increases in brain serotonin metabolism in animal models. The peptide also appears to upregulate expression of BDNF (brain-derived neurotrophic factor) and affect IL-6 cytokine signaling, suggesting immunomodulatory activity consistent with its tuftsin ancestry.

These overlapping mechanisms — enkephalinase inhibition, indirect GABAergic modulation, serotonergic activity, and BDNF upregulation — produce an anxiolytic effect that research subjects describe as "calm alertness" rather than sedation, which is a key differentiator from classical anxiolytic drugs.

Dosing Protocol: Intranasal Administration

Selank is almost exclusively administered intranasally in both research settings and the published literature. Intranasal delivery bypasses first-pass hepatic metabolism and allows direct mucosal absorption, making it significantly more efficient than oral routes for this peptide class.

Standard Research Dosing Ranges:

Most published clinical investigations from Russian research groups have used 400–600 mcg total daily doses divided across two administrations. The peptide's short plasma half-life (~2 minutes) means that effects are driven by downstream receptor changes rather than sustained plasma concentrations, which somewhat decouples dosing frequency from pharmacokinetic modeling.

Researchers typically administer Selank as 1–2 drops per nostril using a sterile intranasal applicator, with each drop delivering approximately 50–100 mcg depending on reconstitution concentration.

Reconstitution for Nasal Administration

Selank is typically supplied as a lyophilized powder and must be reconstituted with bacteriostatic water (BAC water) or sterile saline before intranasal use. The target concentration for comfortable nasal administration is typically 0.15–0.5 mg/mL.

Reconstitution Example:

• Starting material: 5 mg lyophilized Selank
• Add: 10 mL BAC water
• Resulting concentration: 0.5 mg/mL (500 mcg/mL)
• Volume per 250 mcg dose: 0.5 mL (approximately 10 drops from a standard nasal applicator)

For higher-concentration preparations intended to minimize volume per dose:

• Add: 5 mL BAC water to 5 mg powder
• Resulting concentration: 1 mg/mL
• Volume per 250 mcg dose: 0.25 mL

A nasal atomizer (MAD Nasal device or equivalent) is recommended over dropper bottles to ensure consistent droplet size and uniform mucosal distribution. pH-neutral solutions are preferred to minimize nasal irritation; reconstitution in sterile saline (0.9% NaCl) can reduce irritation compared to pure BAC water alone.

Half-Life, Duration, and Pharmacokinetics

One of Selank's most pharmacologically interesting features is the dissociation between its plasma half-life and duration of biological effect. In plasma, enzymatic cleavage reduces Selank's half-life to approximately 2 minutes — a figure that would suggest extremely transient effects. However, behavioral and cognitive effects in research models persist for 4–8 hours post-administration.

This apparent paradox is explained by the downstream mechanism: Selank's primary effects stem from inhibiting enkephalinase, which then allows endogenous enkephalins to exert prolonged activity. The peptide itself disappears rapidly, but the enzymatic inhibition and subsequent receptor-level changes persist. This is sometimes described as a "catalytic" mechanism — brief peptide exposure producing lasting neurochemical changes.

Selank's metabolites include Thr-Lys-Pro-Arg (tuftsin) and Pro-Arg, both of which retain some biological activity, meaning the full pharmacological effect may involve the parent compound and its breakdown products.

Selank vs. Benzodiazepines: Research Comparison

The research comparison between Selank and benzodiazepines highlights a fundamentally different risk profile. Whereas benzodiazepines produce anxiolysis through broad GABA-A receptor agonism — which also causes sedation, cognitive impairment, muscle relaxation, and dependence — Selank's more selective mechanism appears to spare these side effect domains.

Notably, several studies have documented that Selank actually improves working memory and attention alongside anxiolysis, which is the opposite of what is observed with benzodiazepines. This combination of anxiety reduction and cognitive enhancement makes Selank a subject of significant interest in both anxiety and cognitive research.

Memory Enhancement and Cognitive Research

Beyond anxiolysis, Selank has been investigated for cognitive-enhancing properties. A series of studies from Russian institutions found that Selank administration improved learning and memory consolidation in animal models, particularly under conditions of stress-induced cognitive impairment. The hypothesized mechanism involves BDNF upregulation — Selank appears to increase hippocampal BDNF expression, which supports synaptic plasticity and long-term potentiation.

In human clinical studies (primarily from Russia and Ukraine), Selank demonstrated improvements in memory recall and attention in patients with anxiety disorders, with the cognitive benefits appearing to be independent of the anxiolytic effect rather than secondary to reduced anxiety. This distinguishes Selank from compounds like beta-blockers or buspirone, where cognitive improvements are generally attributed to anxiety reduction alone.

The memory enhancement profile has led researchers to categorize Selank as a "nootropic anxiolytic" — a compound that simultaneously reduces anxiety and supports cognitive function, rather than trading one for the other.

Storage and Stability

Proper storage is critical for peptide integrity and research reproducibility.

Lyophilized (unreconstituted) powder:

• Store at -20°C (freezer) for long-term storage (up to 24 months)
• Store at 4°C (refrigerator) for short-term use (up to 6 months)
• Protect from light and moisture
• Keep desiccant in storage container

Reconstituted solution:

• Store at 4°C in refrigerator
• Use within 30 days of reconstitution
• Do not freeze reconstituted peptide (degrades on freeze-thaw cycling)
• Keep in amber glass or UV-protected containers
• Label with reconstitution date and concentration

Repeated freeze-thaw cycles significantly degrade peptide integrity. Researchers using Selank regularly should consider aliquoting the lyophilized powder into single-use research quantities before reconstitution to avoid waste and degradation.

Frequently Asked Questions

Q: Can Selank be administered orally? A: Oral administration of Selank is not practical for research purposes. Like most peptides, Selank is rapidly degraded by gastrointestinal proteases before meaningful systemic absorption can occur. Intranasal administration bypasses this degradation, which is why it is the preferred route in all published research.

Q: Is Selank structurally related to Semax? A: Selank and Semax are both synthetic peptide analogues developed by the same Russian research institution, but they have different parent structures. Selank is derived from tuftsin, an immunomodulatory peptide, while Semax is derived from ACTH (adrenocorticotropic hormone). Both share intranasal administration and similar storage requirements, but their mechanisms and primary research applications differ.

Q: What is the research status of Selank outside of Russia? A: Selank is registered as a pharmaceutical drug in Russia and has been used clinically there for anxiety and cognitive disorders. Outside of Russia, it remains a research compound not approved by the FDA or EMA for clinical use. Research use outside of approved jurisdictions is subject to applicable local regulations.

Use the Peptide Reconstitution Calculator [→ Link to /calculators/reconstitution]

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions